Wyeth Closes ReFacto And Premarin Facilities, Cites Low Demand As Reason
Executive Summary
Wyeth is closing its ReFacto manufacturing plant in St. Louis due to lower demand for the antihemophilic Factor VIII product
You may also be interested in...
Wyeth Marietta, Penn. Facility Shutdown To Mark End Of Influenza Program
Wyeth will shut down the last element of its influenza vaccine program with the close of its Marietta, Penn. facility in December
Wyeth Marietta, Penn. Facility Shutdown To Mark End Of Influenza Program
Wyeth will shut down the last element of its influenza vaccine program with the close of its Marietta, Penn. facility in December
Wyeth ReFacto promotion cited by FDA
Wyeth discontinues ReFacto promotional brochure after FDA cites unsubstantiated safety claims. ReFacto material claimed "albumin-free final formulation for unsurpassed viral safety," FDA's Feb. 2 1letter says. "FDA is unaware of any data supporting the claim." Low ReFacto demand is causing Wyeth to close St. Louis manufacturing facility (2"The Pink Sheet" Jan. 26, 2004, p. 36)...